Scholarlink

<p>The search for effective, sustainable alternatives to antibiotics in aquaculture has intensified interest in probiotics, yet the comparative efficacy of host-derived versus commercial probiotic strains remains poorly understood. This study evaluated the probiotic potential of two indigenous gut isolates including a putatively non-virulent strain of Pseudomonas, <i>Pseudomonas aeruginosa</i> PA4 and <i>Bacillus</i> sp.BA4P, previously screened for safety, against commercial <i>Bacillus</i>- and <i>Pseudomonas</i>-based formulations in red tilapia (<i>Oreochromis</i> sp.) over a 60-day feeding trial. Fish fed the combined indigenous probiotic (PA4 + BA4P) exhibited superior growth performance, feed efficiency, and digestive enzyme activities (protease, lipase, amylase) compared to control and commercial probiotic groups. Enhanced intestinal villus height, goblet cell density, and intraepithelial lymphocyte counts indicated improved gut health and mucosal immunity. Probiotic supplementation also modulated gut microbiota by increasing beneficial bacteria (<i>Bacillus</i>, <i>Lactobacillus</i>, <i>Pseudomonas</i>) and suppressing potential pathogens (<i>Streptococcus</i>, <i>Aeromonas</i>, <i>Vibrio</i>). Systemic immunity was strengthened, as evidenced by elevated leukocyte counts, serum IgM levels, and reduced hepatic stress markers. Following co-challenge with <i>Aeromonas hydrophila</i> and <i>Streptococcus iniae</i>, the PA4 + BA4P group showed the highest survival rate (75%), significantly outperforming the control (44% survival). These findings demonstrate that host-adapted, multi-strain probiotics confer more benefits in growth, digestive capacity, gut integrity, and disease resistance, offering a promising sustainable strategy for tilapia aquaculture.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Host-derived probiotics outperform commercial formulations in improving growth, gut health and disease resistance in red tilapia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Remy Ntakirutimana,
  • K.M. Mujeeb Rahiman,
  • Aishath Ali Farhath,
  • Regina Hershey,
  • Megha Lovejan,
  • M.P. Jijina,
  • Fazeena Fariq,
  • Mariya Jacob Ashin,
  • C. Varsha,
  • K. Nandhakumar,
  • K.V. Neethu,
  • Anatole Bigirimana

摘要

The search for effective, sustainable alternatives to antibiotics in aquaculture has intensified interest in probiotics, yet the comparative efficacy of host-derived versus commercial probiotic strains remains poorly understood. This study evaluated the probiotic potential of two indigenous gut isolates including a putatively non-virulent strain of Pseudomonas, Pseudomonas aeruginosa PA4 and Bacillus sp.BA4P, previously screened for safety, against commercial Bacillus- and Pseudomonas-based formulations in red tilapia (Oreochromis sp.) over a 60-day feeding trial. Fish fed the combined indigenous probiotic (PA4 + BA4P) exhibited superior growth performance, feed efficiency, and digestive enzyme activities (protease, lipase, amylase) compared to control and commercial probiotic groups. Enhanced intestinal villus height, goblet cell density, and intraepithelial lymphocyte counts indicated improved gut health and mucosal immunity. Probiotic supplementation also modulated gut microbiota by increasing beneficial bacteria (Bacillus, Lactobacillus, Pseudomonas) and suppressing potential pathogens (Streptococcus, Aeromonas, Vibrio). Systemic immunity was strengthened, as evidenced by elevated leukocyte counts, serum IgM levels, and reduced hepatic stress markers. Following co-challenge with Aeromonas hydrophila and Streptococcus iniae, the PA4 + BA4P group showed the highest survival rate (75%), significantly outperforming the control (44% survival). These findings demonstrate that host-adapted, multi-strain probiotics confer more benefits in growth, digestive capacity, gut integrity, and disease resistance, offering a promising sustainable strategy for tilapia aquaculture.